Are You Watching These Cannabis Stocks? PharmaCyte Biotech, Inc. (OTCMKTS: PMCB), GW Pharmaceuticals (NASDAQ: GWPH), and CannaGrow Holdings (OTCMKTS: CGRW)

Posted by admin February 10, 2015 0 Comment 1013 views

New York, NY – GDP INSIDER  –  02/10/2015.

This article discusses three companies: CannaGrow Holdings (OTCMKTS: CGRW), PharmaCyte Biotech, Inc. (OTCMKTS: PMCB) and GW Pharmaceuticals (NASDAQ: GWPH)

CannaGrow Holdings (OTCMKTS: CGRW) could re-test its recent highs of $1.00 from early February, representing upside of 28% from its current share price.  The float is relatively tight which has increased CGRW’s volatility, and contributes to the potential for a quick rally as it has done in the past.  In addition, the RSI is currently 49 and an indication the stock is somewhat undervalued.  Historically, CGRW sells off after the RSI peaks at 80-90, which the current reading is far from.   While the stock has recently declined, we see it as temporary in an overall bullish trend for CGRW.  Investors can expect this momentum to resume and drive the shares higher.

What Can Drive Returns Of 30%+ For Investors In Cannagrow Holdings.  Click Here To Understand With Our Free CGRW Analysis.

PharmaCyte Biotech, Inc. (OTCMKTS: PMCB) initiated development of a new diabetes treatment that is in its first preclinical study.  The potential for the treatment is huge with the insulin market estimated at $40 billion annual by 2018.  The new treatment would implant cells into the patient that then produce insulin eliminated the need for other treatments. While the new treatment is in its early stages, the timing may be right to buy PMCB.  The stock is down 30% from its highs.  However, positive data points around this treatment could drive the shares back to those levels and higher.

Should You Invest In Pharmacyte Biotech, Inc? Our Report For Investors On PMCB Shows Why It Could Be Right For Investors’ Portfolios.  

GW Pharmaceuticals (NASDAQ: GWPH) has been range bound between $68 and $80 since late October, 2014.  Over the past year, the stock has traded in an even wider range from $41.86-$111.46.  With volatility somewhat subsiding and a positive long-term outlook in the sector, the timing is right to consider buying GWPH.  It could be poised to retest recent highs of $80 to break out of its current range with fundamentals in its business improving.  The MFI reading of 77 indicates that money is flowing into the stock and it could be poised for another rally.

Is GW Pharmaceuticals A Buy-Low Option? See Why GWPH Is A Stock To Buy And Hold In Your Portfolio.  

About UltimateStockAlerts provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. UltimateStockAlerts has been compensated five thousand dollars for distribution of our opinions of cgrw by microcap innovations. Please visit website, for complete risks and disclosures.

Write Your Comment